

## Price Change Notification on Selected Product Portfolios

**Basel, Switzerland, 07 May, 2021** – Effective 10 May, 2021 or as dictated by the terms of individual contracts, Lonza Specialty Ingredients (LSI) will implement list and off-list price adjustments for selected products globally.

The selected price increases are a result of the prevailing supply market conditions and the related increase in raw material, equipment, logistics, and supply chain costs.

LSI reaffirms its commitment to the reliable supply of products, service and value to its customers. If you have any questions regarding this price increase, please do not hesitate to contact your local sales representative or account manager.

### About Lonza

Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to prevent illness and enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. These enable our customers to commercialize their discoveries and innovations in the healthcare sector.

Founded in 1897 in the Swiss Alps, today Lonza operates across five continents. With approximately 14,000 full-time employees, we are built from high-performing teams and of individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 4.5 billion in 2020 with a CORE EBITDA of CHF 1.4 billion. Find out more at [www.lonza.com](http://www.lonza.com).

Follow @Lonza on [LinkedIn](#)

Follow @LonzaGroup on [Twitter](#)

## **Lonza Contact Details**

### **Birgit Gronkowski**

Head of LSI Communications

Lonza Specialty Ingredients

Tel +41 61 316 2054

[birgit.gronkowski@lonza.com](mailto:birgit.gronkowski@lonza.com)

## **Additional Information and Disclaimer**

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.